Heart rate variability in Parkinson's disease patients treated with tolcapone

Parkinsonism and Related Disorders

Volumn 6, Issue 4, 2000, Pages 223-227

  Meco, G ^a   Vanacore, N ^a   Locuratolo, N ^a   Bonifati, V ^a   Vella, C ^a   Giovani, A ^a   Tubani, L ^a   Baratta, L ^a   Mastrocola, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autonomic cardiovascular function; Parkinson's disease; Tolcapone

Indexed keywords

BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; SELEGILINE; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART RATE VARIABILITY; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0033935528     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(00)00016-X     Document Type: Article

References (23)

1. Bonifati V., Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther. 81:1999;1-36.
2. Rajput A.H., Martin W., Saint-Hilaire M.H., et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 49:1997;1066-1071.
3. Baas H., Bleiske A.G., Ghika J., et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 63:1997;421-428.
4. Waters C.H., Kurth M., Bailey P., et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology. 49:1997;665-671.
5. Adler C.H., Singer C., O'Brien C., et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol. 55:1998;1089-1095.
6. Assal F., Spahr L., Hadengue A., Rubbici-Brandt L., Burkhard P.R. Tolcapone and fulminant hepatitis. The Lancet. 352:1998;958.
7. Tanner C.M., Goetz C.G., Klawans H.L. Autonomic nervous system disorders in Parkinson's disease. Koller W.C. Handbook of Parkinson's disease. 1992;185-215 Marcel Dekker Inc. New York.
8. Turkka J.T., Tolonen U., Myllylä V.V. Cardiovascular reflexes in Parkinson's disease. Eur Neurol. 26:1987;104-112.
9. Meco G., Pratesi L., Bonifati V. Cardiovascular reflexes and autonomic dysfunction in Parkinson's disease. J Neurol. 238:1991;195-199.
10. Javoy-Agid F., Ruberg M., Pique L., et al. Biochemistry of the hypothalamus in Parkinson's disease. Neurology. 34:1984;672-675.
11. Rajput A.H., Rozdilsky B. Dysautonomia in Parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry. 39:1976;1092-1100.
12. Orskov L., Jakobsen J., Dupont E., et al. Autonomic function in parkinsonian patients relates to duration of disease. Neurology. 37:1987;1173-1178.
13. Iwanaga K., Wakabayashi K., Yoshimoto M., et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology. 52:1999;1269-1271.
14. Myllylä V.V., Sotaniemi K.A., Illi A., Suominen K., Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of Levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol. 45:1993;419-423.
15. Mastrocola C., Vanacore N., Giovani A., et al. Twenty-four-hour heart rate variability to assess autonomic function in Parkinson's disease. Acta Neurol Scand. 99:1999;245-247.
16. Gibb W.R.G., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 51:1988;745-752.
17. Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Circulation. 93:1996;1043-1065.
18. Sundberg S., Scheinin M., Illi A., et al. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol. 36:1993;451-456.
19. Illi A., Sundberg S., Koulu M., et al. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther. 32:1994;582-588.
20. Illi A., Sundberg S., Ojala-Karlsson P., et al. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther. 58:1995;221-227.
21. Gordin A., Sundberg S., Scheinin M., Keränen T. Inhibition of catechol-O methyltransferase activity with entacapone does not affect hemodynamics of plasma catecholamine levels during exercise. Neurology. 42:(Suppl. 3):1992;324.
22. Illi A., Sundberg S., Ojala-Karlsson P., et al. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther. 59:1996;450-457.
23. Illi A., Sundberg S., Ojala-Karlsson P., et al. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin. Pharmacol. 51:1996;273-276.